Cancer Biomarkers Market By Type (Genetic Biomarkers, Epigenetic Biomarkers, Metabolic Biomarkers, Proteomic Biomarkers), By Type of Cancer (Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer), By Type of Profiling Technologies (Immunoassays, Omics Technologies, Cytogenetics, Imaging Technologies, Bioinformatics), By Application (Diagnostics, Drug Discovery & Development, Prognostics, Risk Assessment) - Growth, Future Prospects, and Competitive Analysis, 2017-2025
The report titled “Cancer Biomarkers Market- Growth, Future Prospects, and Competitive Analysis, 2017 – 2025” offers strategic insights into the overall cancer biomarkers market along with the market size and estimates for the duration 2015 to 2025. The said research study cover in-depth analysis of multiple market segments based on type, type of cancer, type of profiling technologies, type of application, and different geographies. Biomarkers have many potential applications in oncology, including risk assessment, screening, differential diagnosis, determination of prognosis, prediction of response to treatment, and monitoring of progression of disease. Factors such as rising prevalence of cancer, increasing support from government and non-government organizations for cancer biomarkers research, aging population, and increasing use of biomarkers in the drug discovery and development process.
For the purpose of this study, the global cancer biomarker market is segmented on the basis of type into genetic biomarkers, epigenetic biomarkers, metabolic biomarkers, proteomic biomarkers, & others. Market size estimates and forecast for these segments for the period 2015 to 2025 are provided in terms of USD Mn along with the respective compounded annual growth rates (CAGRs) for the period 2017 to 2025, considering 2016 as the base year.
On the basis of type of cancer such as breast cancer, lung cancer, colorectal cancer, prostate cancer, cervical cancer, & others. Market size estimates and forecast for these segments for the period 2015 to 2025 are provided in terms of USD Mn along with the respective compounded annual growth rates (CAGRs) for the period 2017 to 2025, considering 2016 as the base year.
The global cancer biomarker market is also segmented on the basis of type of profiling technologies such as immunoassays, omics technologies, cytogenetics, imaging technologies, & bioinformatics. Market size estimates and forecast for these segments for the period 2015 to 2025 are provided in terms of USD Mn along with the respective compounded annual growth rates (CAGRs) for the period 2017 to 2025, considering 2016 as the base year.
The global cancer biomarker market is segmented on the basis of type of application such as into diagnostics, drug discovery & development, prognostics, risk assessment, & others. Market size estimates and forecast for these segments for the period 2015 to 2025 are provided in terms of USD Mn along with the respective compounded annual growth rates (CAGRs) for the period 2017 to 2025, considering 2016 as the base year.
The geographical segmentation of cancer biomarkers market comprised regions such as North America, Europe, Asia-Pacific, Latin America & Middle East and Africa. Each geographical region is further split to provide market revenue for select countries such as the U.S., Canada, U.K. Germany, China, Japan, Brazil, Mexico, Saudi Arabia, South Africa, and other countries. Market size and forecast for these segments during 2015 to 2025 and their CAGRs for the period 2017 to 2025 are provided in this report.
The cancer biomarkers market is observed as the most diversified and competitive market comprising large number of players. The market is dominated by several players, depending on their major competencies. The key players in this market are Abbott Laboratories, Affymetrix, Inc., DiagnoCure Inc., Qiagen N.V., Illumina, Inc., Roche Diagnostics Ltd., Quest Diagnostics Inc., Agilent Technologies Inc., Merck & Co. Inc., Hologic, Inc., and Becton Dickinson and Company among others.
Based on by type, the global cancer biomarkers market is segmented as follows:
- Genetic Biomarkers
- Epigenetic Biomarkers
- Metabolic Biomarkers
- Proteomic Biomarkers
- Other Biomarkers
In year 2016, proteomic biomarkers dominated the market by type due to exceptional market potential of protein biomarkers in diagnostics, prognostics, cancer detection and other clinical & therapeutic applications. In addition, increasing focus of pharmaceutical & biotechnology companies in research and development of protein biomarkers is expected to fuel the overall market growth. During the forecast period 2017 – 2025, epigenetics was observed as the fastest growing segment as it gained high acceptance in cancer diagnostics industry. The key factors driving the growth of epigenetics segment are high amount of research carried out by many players for the analysis of key epigenetic modification, and increasing collaboration between diagnostics and pharmaceutical companies for developing precise diagnosis and target specific treatment.
Based on the type of profiling technologies, the global cancer biomarkers market is segmented as follows:
- Immunoassays
- Omics Technologies
- Cytogenetics
- Imaging Technologies
- Bioinformatics
In year 2016, omics technologies accounted for the largest share of the cancer biomarkers market and also the fastest growing segment due to key driving factors such as increased adoption of advanced high throughput technologies in biomarker discovery and development and rising application of omics-based tests for cancer diagnosis and drug development process. In addition, incessant developments in high-throughput omics technologies are also backing the growth of this market, by rising the space of prospective biomarkers in cancer research.
Based on the type of cancer, the global cancer biomarkers market is segmented as follows:
- Breast Cancer
- Lung Cancer
- Colorectal Cancer
- Prostate Cancer
- Cervical Cancer
- Others
In year 2016, breast cancer dominated the cancer biomarkers market by cancer type due to rising prevalence of disease, high awareness associated with early diagnosis, increasing public awareness with assistance of government and non-government organizations, and rising research and development activities in the field of breast cancer diagnosis. During the forecast period 2017 – 2025, lung cancer was observed as the fastest growing segment due to key driving factors such as rising prevalence of lung cancer due to increase in air pollution and frequent smoking observed in young generation.
Based on the type of application, the global cancer biomarkers market is segmented as follows:
- Diagnostics
- Drug Discovery & Development
- Prognostics
- Risk Assessment
- Others
Rising prevalence of cancer, increasing demand for efficient diagnosis techniques against cancer, developing research activities in the field of cancer biomarkers, and increasing awareness associated with early cancer diagnosis are the key factors driving the overall cancer biomarkers market. In year 2016, applications segment was dominated by diagnostics due to key driving factors such as increasing public awareness about the importance of early diagnosis of cancer and diagnostic biomarkers enable doctors to decide effective treatment alternatives.
For the purpose of this study, the global cancer biomarkers market is categorized into:
- North America
- Europe
- Asia Pacific
- Latin America (LATAM)
- Middle East and Africa (MEA)
In base year 2016, North America accounted for the largest share in global cancer biomarkers market due to key driving factors such as high prevalence of cancer, mounting healthcare expenditure leading to rise in demand for efficient diagnostic tests and health care services, and incessant technological advancements in the cancer biomarkers industry. According to the American Cancer Society, in 2017 about 190,500 cancer deaths in the US will be caused by cigarette smoking alone. An estimated 20% of all cancers diagnosed in the US are caused by a combination of excess body weight, physical inactivity, excess alcohol consumption, and poor nutrition, and thus could also be prevented. During forecast period 2017 – 2025, Asia Pacific was observed as the fastest growing region in cancer biomarkers market due to rising prevalence and awareness of cancer, supportive government policies, market expansion by key market players, and rising application of biomarker tests for cancer diagnosis.
Chapter 1. Preface
1.1. Report Scope and Description
1.2. Research Methodology
1.2.1. Phase I-Secondary Research
1.2.2. Phase II-Primary Research
1.2.3. Phase III-Expert Panel Review
1.2.4. Assumptions
1.2.5. Approach Adopted
Chapter 2. Executive Summary
2.1. Global Cancer Biomarkers Market Portraiture
2.1.1. Global Cancer Biomarkers Market, by Type, 2016
2.1.2. Global Cancer Biomarkers Market, by Type of Cancer, 2016
2.1.3. Global Cancer Biomarkers Market, by Profiling Technologies, 2016
2.1.4. Global Cancer Biomarkers Market, by Application, 2016
2.1.5. Global Cancer Biomarkers Market, by Geography, 2016
Chapter 3. Cancer Biomarkers Market: Market Dynamics and Future Outlook
3.1. Market Overview
3.2. Cancer: Epidemiology & Diagnosis Rate
3.3. Cancer Biomarkers: Price Analysis
3.4. Cancer Biomarkers: Future Trends
3.5. Drivers
3.6. Challenges
3.7. Opportunities
3.8. Attractive Investment Proposition, by Geography, 2016
3.9. Major Agreements, Partnerships and Collaborations
3.10. Competitive Landscape
3.10.1. Competitive Landscape, by Key Players, 2016
Chapter 4. Global Cancer Biomarkers Market, by Type, 2015 – 2025 (US$ Mn)
4.1. Overview
4.1.1. Attractive Investment Proposition: Global Cancer Biomarkers Market, by Type
4.2. Genetic Biomarkers
4.3. Epigenetic Biomarkers
4.4. Metabolic Biomarkers
4.5. Proteomic Biomarkers
4.6. Others
Chapter 5. Global Cancer Biomarkers Market, by Type of Cancer, 2015 – 2025 (US$ Mn)
5.1. Overview
5.1.1. Attractive Investment Proposition: Global Cancer Biomarkers Market, by Type of Cancer
5.2. Breast Cancer
5.3. Lung Cancer
5.4. Colorectal Cancer
5.5. Prostate Cancer
5.6. Cervical Cancer
5.7. Others
Chapter 6. Global Cancer Biomarkers Market, by Type of Profiling Technologies, 2015 – 2025 (US$ Mn)
6.1. Overview
6.1.1. Attractive Investment Proposition: Global Cancer Biomarkers Market, by Type of Profiling Technologies
6.2. Immunoassays
6.3. Omics Technologies
6.4. Cytogenetics
6.5. Imaging Technologies
6.6. Bioinformatics
Chapter 7. Global Cancer Biomarkers Market, by Type of Application, 2015 – 2025 (US$ Mn)
7.1. Overview
7.1.1. Attractive Investment Proposition: Global Cancer Biomarkers Market, by Type of Application
7.2. Diagnostics
7.3. Drug Discovery & Development
7.4. Prognostics
7.5. Risk Assessment
7.6. Others
Chapter 8. Global Cancer Biomarkers Market, by Geography, 2015 – 2025 (US$ Mn)
8.1. Overview
8.2. North America Cancer Biomarkers Market Analysis, 2015 – 2025
8.2.1. North America Cancer Biomarkers Market, by Type, 2015 – 2025 (US$ Mn)
8.2.2. North America Cancer Biomarkers Market, by Type of Cancer, 2015 – 2025 (US$ Mn)
8.2.3. North America Cancer Biomarkers Market, by Profiling Technologies, 2015 – 2025 (US$ Mn)
8.2.4. North America Cancer Biomarkers Market, by Application, 2015 – 2025 (US$ Mn)
8.2.5. North America Cancer Biomarkers Market, by Country, 2015 – 2025 (US$ Mn)
8.2.5.1. U.S.
8.2.5.2. Canada
8.3. Europe Cancer Biomarkers Market Analysis, 2015 – 2025
8.3.1. Europe Cancer Biomarkers Market, by Type, 2015 – 2025 (US$ Mn)
8.3.2. Europe Cancer Biomarkers Market, by Type of Cancer, 2015 – 2025 (US$ Mn)
8.3.3. Europe Cancer Biomarkers Market, by Profiling Technologies, 2015 – 2025 (US$ Mn)
8.3.4. Europe Cancer Biomarkers Market, by Application, 2015 – 2025 (US$ Mn)
8.3.5. Europe Cancer Biomarkers Market, by Country, 2015 – 2025 (US$ Mn)
8.3.5.1. U.K.
8.3.5.2. Germany
8.3.5.3. France
8.3.5.4. Spain
8.3.5.5. Italy
8.3.5.6. Rest of Europe
8.4. Asia Pacific Cancer Biomarkers Market Analysis, 2015 – 2025
8.4.1. Asia Pacific Cancer Biomarkers Market, by Type, 2015 – 2025 (US$ Mn)
8.4.2. Asia Pacific Cancer Biomarkers Market, by Type of Cancer, 2015 – 2025 (US$ Mn)
8.4.3. Asia Pacific Cancer Biomarkers Market, by Profiling Technologies, 2015 – 2025 (US$ Mn)
8.4.4. Asia Pacific Cancer Biomarkers Market, by Application, 2015 – 2025 (US$ Mn)
8.4.5. Asia Pacific Cancer Biomarkers Market, by Country, 2015 – 2025 (US$ Mn)
8.4.5.1. Japan
8.4.5.2. China
8.4.5.3. India
8.4.5.4. Rest of APAC
8.5. Latin America Cancer Biomarkers Market Analysis, 2015 – 2025
8.5.1. Latin America Cancer Biomarkers Market, by Type, 2015 – 2025 (US$ Mn)
8.5.2. Latin America Cancer Biomarkers Market, by Type of Cancer, 2015 – 2025 (US$ Mn)
8.5.3. Latin America Cancer Biomarkers Market, by Profiling Technologies, 2015 – 2025 (US$ Mn)
8.5.4. Latin America Cancer Biomarkers Market, by Application, 2015 – 2025 (US$ Mn)
8.5.5. Latin America Cancer Biomarkers Market, by Country, 2015 – 2025 (US$ Mn)
8.5.5.1. Brazil
8.5.5.2. Mexico
8.5.5.3. Rest of Latin America
8.6. Middle East & Africa (MEA) Cancer Biomarkers Market Analysis, 2015 – 2025
8.6.1. MEA Cancer Biomarkers Market, by Type, 2015 – 2025 (US$ Mn)
8.6.2. MEA Cancer Biomarkers Market, by Type of Cancer, 2015 – 2025 (US$ Mn)
8.6.3. MEA Cancer Biomarkers Market, by Profiling Technologies, 2015 – 2025 (US$ Mn)
8.6.4. MEA Cancer Biomarkers Market, by Application, 2015 – 2025 (US$ Mn)
8.6.5. MEA Cancer Biomarkers Market, by Region, 2015 – 2025 (US$ Mn)
8.6.5.1. UAE
8.6.5.2. Saudi Arabia
8.6.5.3. South Africa
8.6.5.4. Rest of MEA
Chapter 9. Company Profiles
9.1. Abbott Laboratories
9.1.1. Business Description
9.1.2. Financial Information (Subject to data availability)
9.1.3. Product Portfolio
9.1.4. Key Developments
9.2. Affymetrix, Inc.
9.3. Illumina, Inc.
9.4. Qiagen N.V.
9.5. Roche Diagnostics Ltd.
9.6. Agilent Technologies, Inc.
9.7. Quest Diagnostics Inc.
9.8. Merck & Co. Inc.
9.9. Hologic, Inc.
9.10. Becton, Dickinson and Company
9.11. Sino Biological Inc.
TABLE 1 Global Cancer Biomarkers Market, by Type, 2015 – 2025 (US$ Mn)
TABLE 2 Global Cancer Biomarkers Market, by Type of Cancer, 2015 – 2025 (US$ Mn)
TABLE 3 Global Cancer Biomarkers Market, by Type of Profiling Technologies, 2015 – 2025 (US$ Mn)
TABLE 4 Global Cancer Biomarkers Market, by Type of Application, 2015 – 2025 (US$ Mn)
TABLE 5 Global Cancer Biomarkers Market, by Type of Geography, 2015 – 2025 (US$ Mn)
TABLE 6 North America Cancer Biomarkers Market, by Type, 2015 – 2025 (US$ Mn)
TABLE 7 North America Cancer Biomarkers Market, by Type of Cancer, 2015 – 2025 (US$ Mn)
TABLE 8 North America Cancer Biomarkers Market, by Type of Profiling Technologies, 2015 – 2025 (US$ Mn)
TABLE 9 North America Cancer Biomarkers Market, by Application, 2015 – 2025 (US$ Mn)
TABLE 10 North America Cancer Biomarkers Market, by Country, 2015 – 2025 (US$ Mn)
TABLE 11 Europe Cancer Biomarkers Market, by Type, 2015 – 2025 (US$ Mn)
TABLE 12 Europe Cancer Biomarkers Market, by Type of Cancer, 2015 – 2025 (US$ Mn)
TABLE 13 Europe Cancer Biomarkers Market, by Type of Profiling Technologies, 2015 – 2025 (US$ Mn)
TABLE 14 Europe Cancer Biomarkers Market, by Application, 2015 – 2025 (US$ Mn)
TABLE 15 Europe Cancer Biomarkers Market, by Country, 2015 – 2025 (US$ Mn)
TABLE 16 Asia Pacific Cancer Biomarkers Market, by Type, 2015 – 2025 (US$ Mn)
TABLE 17 Asia Pacific Cancer Biomarkers Market, by Type of Cancer, 2015 – 2025 (US$ Mn)
TABLE 18 Asia Pacific Cancer Biomarkers Market, by Type of Profiling Technologies, 2015 – 2025 (US$ Mn)
TABLE 19 Asia Pacific Cancer Biomarkers Market, by Application, 2015 – 2025 (US$ Mn)
TABLE 20 Asia Pacific Cancer Biomarkers Market, by Country, 2015 – 2025 (US$ Mn)
TABLE 21 Latin America Cancer Biomarkers Market, by Type, 2015 – 2025 (US$ Mn)
TABLE 22 Latin America Cancer Biomarkers Market, by Type of Cancer, 2015 – 2025 (US$ Mn)
TABLE 23 Latin America Cancer Biomarkers Market, by Type of Profiling Technologies, 2015 – 2025 (US$ Mn)
TABLE 24 Latin America Cancer Biomarkers Market, by Application, 2015 – 2025 (US$ Mn)
TABLE 25 Latin America Cancer Biomarkers Market, by Country, 2015 – 2025 (US$ Mn)
TABLE 26 Middle East and Africa Cancer Biomarkers Market, by Type, 2015 – 2025 (US$ Mn)
TABLE 27 Middle East and Africa Cancer Biomarkers Market, by Type of Cancer, 2015 – 2025 (US$ Mn)
TABLE 28 Middle East and Africa Cancer Biomarkers Market, by Type of Profiling Technologies, 2015 – 2025 (US$ Mn)
TABLE 29 Middle East and Africa Cancer Biomarkers Market, by Application, 2015 – 2025 (US$ Mn)
TABLE 30 Middle East and Africa Cancer Biomarkers Market, by Region, 2015 – 2025 (US$ Mn)
TABLE 31 Abbott Laboratories: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 32 Affymetrix, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 33 DiagnoCure Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 34 Qiagen N.V.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 35 Illumina, Inc: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 36 Roche Diagnostics Ltd.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 37 Quest Diagnostics Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 38 Agilent Technologies Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 39 Merck & Co. Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 40 Hologic, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 41 Becton Dickinson and Company: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 42 Sino Biological Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage
FIG. 1 Cancer Biomarkers: Market Segmentation
FIG. 2 Global Cancer Biomarkers Market Share, by Type, 2016 (Value %)
FIG. 3 Global Cancer Biomarkers Market, by Type of Cancer, 2016 (US$ Mn)
FIG. 4 Global Cancer Biomarkers Market Share, by Type of Profiling Technologies, 2016 (Value %)
FIG. 5 Global Cancer Biomarkers Market, by Type of Application, 2016 (US$ Mn)
FIG. 6 Global Cancer Biomarkers Market, by Geography, 2016 (Value %)
FIG. 7 Attractive Investment Proposition, by Geography, 2016
FIG. 8 Market Competition Landscape, by Key Players, 2016
FIG. 9 Global Genetic Biomarkers Market, 2015 – 2025 (US$ Mn)
FIG. 10 Global Epigenetic Biomarkers Market, 2015 – 2025 (US$ Mn)
FIG. 11 Global Metabolic Biomarkers Market, 2015 – 2025 (US$ Mn)
FIG. 12 Global Proteomic Biomarkers Market, 2015 – 2025 (US$ Mn)
FIG. 13 Global Other Biomarkers Market, 2015 – 2025 (US$ Mn)
FIG. 14 Global Breast Cancer Market in Cancer Biomarkers, 2015 – 2025 (US$ Mn)
FIG. 15 Global Lung Cancer Market in Cancer Biomarkers, 2015 – 2025 (US$ Mn)
FIG. 16 Global Colorectal Cancer Market in Cancer Biomarkers, 2015 – 2025 (US$ Mn)
FIG. 17 Global Prostate Cancer Market in Cancer Biomarkers, 2015 – 2025 (US$ Mn)
FIG. 18 Global Cervical Cancer Market in Cancer Biomarkers, 2015 – 2025 (US$ Mn)
FIG. 19 Global Other Cancers Market in Cancer Biomarkers, 2015 – 2025 (US$ Mn)
FIG. 20 Global Immunoassays Market in Cancer Biomarkers, 2015 – 2025 (US$ Mn)
FIG. 21 Global Omics Technologies Market in Cancer Biomarkers, 2015 – 2025 (US$ Mn)
FIG. 22 Global Cytogenetics Market in Cancer Biomarkers, 2015 – 2025 (US$ Mn)
FIG. 23 Global Imaging Technologies Market in Cancer Biomarkers, 2015 – 2025 (US$ Mn)
FIG. 24 Global Bioinformatics Market in Cancer Biomarkers, 2015 – 2025 (US$ Mn)
FIG. 25 Global Diagnostics Application Market in Cancer Biomarkers, 2015 – 2025 (US$ Mn)
FIG. 26 Global Drug Discovery & Development Application Market in Cancer Biomarkers, 2015 – 2025 (US$ Mn)
FIG. 27 Global Prognostics Application Market in Cancer Biomarkers, 2015 – 2025 (US$ Mn)
FIG. 28 Global Risk Assessment Application Market in Cancer Biomarkers, 2015 – 2025 (US$ Mn)
FIG. 29 Global Other Applications Market in Cancer Biomarkers, 2015 – 2025 (US$ Mn)
FIG. 30 U.S. Cancer Biomarkers Market, 2015 – 2025 (US$ Mn)
FIG. 31 Canada Cancer Biomarkers Market, 2015 – 2025 (US$ Mn)
FIG. 32 U.K. Cancer Biomarkers Market, 2015 – 2025 (US$ Mn)
FIG. 33 Germany Cancer Biomarkers Market, 2015 – 2025 (US$ Mn)
FIG. 34 France Cancer Biomarkers Market, 2015-2025 (US$ Mn)
FIG. 35 Spain Cancer Biomarkers Market, 2015-2025 (US$ Mn)
FIG. 36 Italy Cancer Biomarkers Market, 2015-2025 (US$ Mn)
FIG. 37 Rest of Europe Cancer Biomarkers Market, 2015 – 2025 (US$ Mn)
FIG. 38 Japan Cancer Biomarkers Market, 2015 – 2025 (US$ Mn)
FIG. 39 China Cancer Biomarkers Market, 2015 – 2025 (US$ Mn)
FIG. 40 India Cancer Biomarkers Market, 2015 – 2025 (US$ Mn)
FIG. 41 Rest of Asia Pacific Cancer Biomarkers Market, 2015 – 2025 (US$ Mn)
FIG. 42 Brazil Cancer Biomarkers Market, 2015 – 2025 (US$ Mn)
FIG. 43 Mexico Cancer Biomarkers Market, 2015 – 2025 (US$ Mn)
FIG. 44 Rest of Latin America Cancer Biomarkers Market, 2015 – 2025 (US$ Mn)
FIG. 45 UAE Cancer Biomarkers Market, 2015 – 2025 (US$ Mn)
FIG. 46 Saudi Arabia Cancer Biomarkers Market, 2015 – 2025 (US$ Mn)
FIG. 47 South Africa Cancer Biomarkers Market, 2015 – 2025 (US$ Mn)
FIG. 48 Rest of Middle East and Africa Cancer Biomarkers Market, 2015 – 2025 (US$ Mn)
Choose License
Contact Information
: sales@briskinsights.com
: +448081890034 (UK)